ATE540315T1 - In-vivo-isotopenkenmarkierungsverfahren für quantitative glycomics - Google Patents

In-vivo-isotopenkenmarkierungsverfahren für quantitative glycomics

Info

Publication number
ATE540315T1
ATE540315T1 AT08845577T AT08845577T ATE540315T1 AT E540315 T1 ATE540315 T1 AT E540315T1 AT 08845577 T AT08845577 T AT 08845577T AT 08845577 T AT08845577 T AT 08845577T AT E540315 T1 ATE540315 T1 AT E540315T1
Authority
AT
Austria
Prior art keywords
labeling methods
isotope labeling
cells
glycomic
glycans
Prior art date
Application number
AT08845577T
Other languages
English (en)
Inventor
Robert Wells
Ronald Orlando
Stephen Dalton
Kelley Moremen
J Michael Pierce
James Atwood
Michael Tiemeyer
William York
Original Assignee
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia filed Critical Univ Georgia
Application granted granted Critical
Publication of ATE540315T1 publication Critical patent/ATE540315T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT08845577T 2007-10-29 2008-10-29 In-vivo-isotopenkenmarkierungsverfahren für quantitative glycomics ATE540315T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92007P 2007-10-29 2007-10-29
PCT/US2008/012283 WO2009058307A1 (en) 2007-10-29 2008-10-29 In vivo isotopic labeling method for quantitative glycomics

Publications (1)

Publication Number Publication Date
ATE540315T1 true ATE540315T1 (de) 2012-01-15

Family

ID=40591359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08845577T ATE540315T1 (de) 2007-10-29 2008-10-29 In-vivo-isotopenkenmarkierungsverfahren für quantitative glycomics

Country Status (5)

Country Link
US (1) US9329169B2 (de)
EP (1) EP2205972B1 (de)
CN (1) CN101910841A (de)
AT (1) ATE540315T1 (de)
WO (1) WO2009058307A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
GB201213127D0 (en) * 2012-07-24 2012-09-05 Univ Dundee Novel isotopic labelling method
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9366678B2 (en) * 2012-10-25 2016-06-14 Wisconsin Alumni Research Foundation Neutron encoded mass tags for analyte quantification
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015134640A1 (en) * 2014-03-05 2015-09-11 GlycoScientific LLC Isotopically labeled glycans and methods for producing the same
WO2017090047A1 (en) 2015-11-27 2017-06-01 Technology Innovation Momentum Fund (Israel) Limited Partnership Glucosamine and derivatives thereof in imaging
KR20180103961A (ko) * 2016-01-23 2018-09-19 바이오콘 리미티드 인슐린 유사체에 대한 생물학적 분석 방법
CN110243917A (zh) * 2018-03-09 2019-09-17 中国科学院天津工业生物技术研究所 一种快速检测小分子化合物的方法
CN108982569A (zh) * 2018-07-20 2018-12-11 中国科学院昆明植物研究所 一种同时定量血浆内、外源性葡萄糖的二维核磁共振方法
US11345929B2 (en) * 2018-10-25 2022-05-31 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
CN111208299B (zh) * 2018-11-21 2021-05-28 中国科学院大连化学物理研究所 一种交联肽段定性定量分析方法
WO2023092108A2 (en) * 2021-11-19 2023-05-25 Insitro, Inc. Autonomous cell imaging and modeling system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068295A4 (de) * 1998-04-09 2002-08-21 Bresagen Ltd Zell-differenzierungs/proliferations- und erhaltungsfaktor und seine verwendungen
JP2002523114A (ja) 1998-08-31 2002-07-30 ユニバーシテイ オブ ワシントン バイオポリマーの分析のための安定なアイソトープ代謝性ラベリング
US6391649B1 (en) 1999-05-04 2002-05-21 The Rockefeller University Method for the comparative quantitative analysis of proteins and other biological material by isotopic labeling and mass spectroscopy
EP1913385B1 (de) * 2005-07-11 2013-08-21 Glykos Finland Oy Gewebekohlenhydratzusammensetzungen und analyse davon
US20080113441A1 (en) 2006-11-14 2008-05-15 Ron Orlando Isobaric labeling and methods of use thereof

Also Published As

Publication number Publication date
EP2205972A1 (de) 2010-07-14
CN101910841A (zh) 2010-12-08
EP2205972B1 (de) 2012-01-04
US20100297609A1 (en) 2010-11-25
EP2205972A4 (de) 2011-02-16
US9329169B2 (en) 2016-05-03
WO2009058307A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
ATE540315T1 (de) In-vivo-isotopenkenmarkierungsverfahren für quantitative glycomics
CA3100631C (en) Method and system for personalized, molecular based health management and digital consultation and treatment
Ibáñez et al. Toward a predictive model of Alzheimer’s disease progression using capillary electrophoresis–mass spectrometry metabolomics
Obeid et al. Methylation status and neurodegenerative markers in Parkinson disease
US20220187315A1 (en) Methods and compositions for diagnosing depression
JP6509201B2 (ja) 神経変性疾患に関連する方法及び組成物
Błażewicz et al. Iodine in autism spectrum disorders
Köttgen et al. Genome-wide association studies of metabolite concentrations (mGWAS): relevance for nephrology
BR112013025329A2 (pt) identificar e enumerar células prematuramente granuladas (ecgs)
US20190178900A1 (en) Autism subsets
Tang et al. Urinary metabolomics reveals alterations of aromatic amino acid metabolism of Alzheimer’s disease in the transgenic CRND8 mice
CN114555631A (zh) 检测MTBR tau同种型的方法及其用途
CA3193117A1 (en) Method of diagnosis and treatment of autism spectrum disorder
Gaunitz et al. What can N-glycomics and N-glycoproteomics of cerebrospinal fluid tell us about Alzheimer disease?
Floryan et al. Long-term physiological flow rescues regressed microvascular networks and increases their longevity
Huemer et al. Low levels of asymmetric dimethylarginine in children with diabetes mellitus type I compared with healthy children
AU2006228990A8 (en) A method of diagnosis and treatment and agents useful for same
Gervasoni et al. Ultra-performance liquid chromatography-mass spectrometry analysis of post-mortem brain tissue reveals specific amino acid profile dysregulation in Parkinson’s Disease and Alzheimer’s Disease patients
Ramos-Rodriguez et al. The L-Arginine pathway may act as a mediator in the association between impaired one-carbon metabolism and hypertension
Miller et al. Quantitative proteomics in laser capture microdissected sleep nuclei from rat brain
Reis et al. Blood Gene Expression of Zinc Transporters as Biological Indicators of Zinc Nutrition
US20170219597A1 (en) Methods and compositions for selective detection of homosysteine
JPWO2013012038A1 (ja) うつ病決定方法、セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
Sprecher et al. Disease-associated programming of cell memory in glycogen storage disorder type 1a
WO2025080644A1 (en) System and method for perturbational profiling of blood cell traits